Abbott Laboratories (NYSE:ABT) is addressing ongoing headwinds in its Nutrition segment with changes to pricing, promotions, and cost structures, with a shift signaled to begin in the fourth quarter.
The company is moving ahead with the pending acquisition of Exact Sciences to expand its presence in cancer diagnostics.
Abbott is also rolling out new products in diabetes care and cardiovascular devices, supported by recent regulatory approvals.
The company is moving ahead with the pending acquisition of Exact Sciences to expand its presence in cancer diagnostics.
Abbott is also rolling out new products in diabetes care and cardiovascular devices, supported by recent regulatory approvals.
For investors watching NYSE:ABT, the key story…
